If you are still automatically holding tamoxifen or delaying reconstruction because a patient is on targeted therapy, it is time to recalibrate. The latest systematic review and multidisciplinary consensus published in Plastic and Reconstructive Surgery takes a hard look at adjuvant anticancer agents and their real perioperative impact on breast reconstruction. Most of these medications do not require interruption for primary or staged reconstruction. This week, Surgical Aesthetics 411 explores why the era of blanket medication holds could be over.
What Actually Increases Surgical Risk?
Your reconstruction patients are commonly on:
- Tamoxifen
- Aromatase inhibitors
- HER2-targeted agents such as trastuzumab or pertuzumab
- Ovarian suppression therapies
- Increasingly, immunotherapy in select cases
The concern has always centered around three things:
- Thromboembolic risk
- Impaired wound healing
- Cytopenias leading to infection or bleeding
The authors screened nearly 1,200 studies and distilled the usable data down to 19 studies involving over 5,700 patients. That number alone tells you something. Despite how common this scenario is, the high-quality data remain limited. Much of what many surgeons do has historically been based on extrapolation rather than evidence.
The consensus recommendations reflect that reality. Most endocrine and HER2-directed therapies do not meaningfully increase perioperative complication rates in reconstruction. Routine discontinuation is not supported by strong evidence.
The Drug Everyone Fears
Tamoxifen has long been treated as a surgical liability because of its association with venous thromboembolism. That concern is legitimate. But the magnitude of risk in the perioperative reconstructive setting appears lower than many assume, particularly in patients without additional VTE risk factors.
The consensus does not mandate universal cessation. Instead, it favors individualized assessment:
- Evaluate baseline VTE risk
- Consider procedure type and operative time
- Optimize mechanical and pharmacologic prophylaxis
If you are performing microsurgical reconstruction in a patient with obesity, smoking history, and prior thrombosis, the calculus changes. If you are performing expander exchange in a low-risk patient, automatic discontinuation may not add meaningful safety and may complicate oncologic management.
Coordination with medical oncology becomes critical. You should not be making unilateral decisions about stopping systemic therapy that affects recurrence risk.
Aromatase Inhibitors
Aromatase inhibitors are not strongly associated with thrombotic risk. Concerns around bone density and arthralgia are clinically relevant long-term but do not translate into clear perioperative wound or infection signals.
In practical terms, these agents rarely need to be held for implant-based or autologous reconstruction. Stopping them may create unnecessary gaps in therapy without measurable surgical benefit.
HER2-Targeted Therapy
Trastuzumab and pertuzumab carry well-known cardiotoxicity considerations. That matters if you are planning a long case or microsurgical reconstruction. It does not automatically mean you need to stop therapy.
Cardiac function assessment is more important than medication interruption. If left ventricular function is stable and oncology is comfortable proceeding, reconstruction can typically move forward without a forced pause in treatment.
The consensus supports this approach. Monitor intelligently. Do not default to cancellation.
The Blind Spots
One of the more important findings in this review is what we do not know. There were no meaningful reconstruction studies examining GnRH agonists or pembrolizumab.
That gap matters. Immunotherapy is increasingly present in neoadjuvant and adjuvant protocols. Immune-related adverse events, delayed wound healing, and inflammatory responses are theoretical concerns. Hard data in reconstructive surgery are sparse.
In these patients, your best tool is proactive communication with oncology and careful perioperative laboratory evaluation. Check leukocytes. Check platelets. Look for immune-related complications in the medical history. Be vigilant rather than reactive.
Labs Over Guesswork
One of the most practical recommendations in the consensus is simple: Check the labs when indicated.
If a patient is on systemic therapy with potential hematologic effects, obtain a CBC close to surgery. Do not rely on outdated labs. Leukopenia and thrombocytopenia are measurable risks, not speculative. This seems obvious, yet it is inconsistently applied.
Immediate vs Delayed Reconstruction
The article focuses on medication management, but you should also consider context:
- Immediate reconstruction after neoadjuvant therapy carries different inflammatory and wound-healing dynamics than delayed revision procedures.
- Implant-based reconstruction may respond differently than autologous free tissue transfer.
For high-risk systemic regimens, autologous reconstruction demands stricter physiologic scrutiny than expander placement. That means stratified planning over automatic deferral.
Fear Is Not a Protocol
Many surgeons hold anticancer agents preemptively to reduce anxiety rather than evidence-based risk. That defensive reflex can:
- Delay reconstruction
- Interrupt oncologic continuity
- Undermine patient trust
- Increase system inefficiency
This review pushes you toward a more disciplined approach. Hold medications when there is a defined, meaningful risk. Continue them when evidence suggests safety. Based on this new data, here’s what you can change tomorrow:
- Build a standardized preoperative protocol for patients on systemic therapy.
- Incorporate oncology input early in surgical planning.
- Risk-stratify tamoxifen patients rather than universally stopping therapy.
- Check labs selectively and close to surgery.
- Educate your team so medication management is consistent across providers.
Breast reconstruction increasingly overlaps with complex systemic oncology. Your role is not just to operate. It is to integrate surgical planning into a dynamic, multidisciplinary cancer care pathway.
The evidence now supports a more confident stance. Most anticancer agents can safely coexist with reconstruction. Your job is to know when they cannot.
SOURCE: Plastic and Reconstructive Surgery
This content is intended for educational purposes only and does not substitute for clinical judgment. Treatment decisions should be based on individual patient needs, professional guidelines, and a comprehensive clinical evaluation.
